Sep 13, 2021 7:00am EDT Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
Sep 07, 2021 7:00am EDT Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
Sep 05, 2021 6:15am EDT Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
Jul 28, 2021 8:11am EDT Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021
May 19, 2021 5:00pm EDT Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
May 11, 2021 8:00am EDT First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
Apr 27, 2021 4:30pm EDT Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT
Apr 22, 2021 8:00am EDT Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021
